BioLineRx Ltd.
BLRXNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for BLRX. That does not mean none is planned.
Get an email about BLRX's next catalysts
Track BioLineRx (BLRX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 0 past
BLRX Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.38 | FQ end Sep/2026 | Call: tbd
Market Overview
Stock performance and key metrics
BioLineRx Ltd. (Hebrew: ΧΧΧΧΧΧΧ ΧΧ¨ ΧΧ§Χ‘), or BioLine, is a publicly traded drug development company. Headquartered in Israel, its shares are traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange.
WebsiteBL-8040 + G-CSF
Multiple Myeloma
horse anti-thymocyte globulin (hATG)
Aplastic Anemia
BL-7040
Ulcerative Colitis
BL - 1020
Schizophrenia
BL 1020 High Dose
Schizophrenia
Ara-C
Acute Myeloid Leukemia
BL-8040
Metastatic Pancreatic Adenocarcinoma
BL-7010
Celiac Disease
Morphine
Acute Pain
Sorbitol+Phenylephrine+Morphine
Acute Pain
BL-1020
Schizophrenia
Sorbitol low concentration+Phenylephrine+Morphine
Acute Pain
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
BL-8040 + G-CSF | Phase 3 | Multiple Myeloma | - | - |
horse anti-thymocyte globulin (hATG) | Phase 2 | Aplastic Anemia | - | - |
BL-7040 | Phase 2 | Ulcerative Colitis | - | - |
BL - 1020 | Phase 2 | Schizophrenia | - | - |
BL 1020 High Dose | Phase 2 | Schizophrenia | - | - |
Ara-C | Phase 2 | Acute Myeloid Leukemia | - | - |
BL-8040 | Phase 2 | Metastatic Pancreatic Adenocarcinoma | - | - |
BL-7010 | Phase 2 | Celiac Disease | - | - |
Morphine | Phase 2 | Acute Pain | - | - |
Sorbitol+Phenylephrine+Morphine | Phase 2 | Acute Pain | - | - |
BL-1020 | Phase 2 | Schizophrenia | - | - |
Sorbitol low concentration+Phenylephrine+Morphine | Phase 2 | Acute Pain | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in BioLineRx Ltd.'s drug pipeline?β
CatalystAlert tracks 12 drug candidates in BioLineRx Ltd.'s (BLRX) pipeline across Phase 3, Phase 2. Its lead program is BL-8040 + G-CSF (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BioLineRx Ltd.'s next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for BioLineRx Ltd. (BLRX) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track BLRX biotech catalysts?β
Add BLRX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BioLineRx Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.